Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Previously Untreated del(5q) AML in Older Patients
NCT00352365Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2006
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jun 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00352365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352365.